Pacific View Asset Management’s Aimmune Therapeutics AIMT Stock Holding History

Pacific View Asset Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-222,117	Closed	-$4.62M	–	47
2019 Q2	$4.62M	Buy	222,117 +4,387	+2%	+$90.3K	5.02%	5
2019 Q1	$4.87M	Buy	217,730 +24,303	+13%	+$572K	5.06%	5
2018 Q4	$4.63M	Buy	193,427 +3,570	+2%	+$92.4K	5.44%	3
2018 Q3	$5.18M	Sell	189,857 -4,771	-2%	-$135K	4.12%	6
2018 Q2	$5.23M	Buy	194,628 +85,644	+79%	+$2.62M	4.14%	6
2018 Q1	$3.47M	Buy	+108,984	New	+$3.84M	2.61%	8

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pacific View Asset Management's AIMT Position: Q3 2019 in Review

Pacific View Asset Management sold out of Aimmune Therapeutics (AIMT) in Q3 2019, closing a stake of 222,117 shares — an estimated $4.62M sold.

Pacific View Asset Management first reported a position in AIMT in Q1 2018 and held it in 6 quarters. The position peaked at $5.23M in Q2 2018. 146 funds tracked by Wall St. Rank hold AIMT as of Q3 2019.

Pacific View Asset Management reported no remaining Aimmune Therapeutics position as of Q3 2019 after selling out during the quarter.
Pacific View Asset Management sold 222,117 Aimmune Therapeutics shares in Q3 2019, an estimated $4.62M.
Pacific View Asset Management first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 6 quarters.
Pacific View Asset Management's Aimmune Therapeutics position peaked at $5.23M in Q2 2018.
146 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2019.

Based on Pacific View Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.